VivoSense, Inc., a Newport Beach, Calif.-based agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, closed a $25M Series A financing round.
Backers included the Perceptive Xontogeny Venture (PXV) Fund and Debiopharm Innovation Fund.
The company intends to use the funds to accelerate the development of novel digital biomarkers, improve digital clinical outcome assessments, expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital clinical outcome assessments (COAs) for life science research.
Led by Dudley Tabakin, chief executive officer, VivoSense is innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using their expansive toolkit of proprietary software. The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. The technology allows interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.
Following the deal, the VivoSense board of directors will consist of current members and co-founders Dudley Tabakin and Lance Myers, as well as new additions, Chris Garabedian and Tanja Dowe.
FinSMEs
30/03/2022